Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Low-density lipoprotein receptor (LDLR) mRNA degradation refers to the cellular processes that regulate the stability and turnover of LDLR messenger RNA, thereby controlling the amount of LDLR protein produced in cells. The LDLR is a key cell-surface receptor responsible for removing cholesterol-rich low-density lipoproteins (LDL) from circulation. Regulation at the mRNA level, particularly through RNA-binding proteins like hnRNPD, is crucial for maintaining cholesterol homeostasis. Targeting this pathway presents a potential therapeutic strategy for managing hypercholesterolemia.
Berberine stabilizes LDLR mRNA by interfering with ARE-binding proteins’ interaction with the 3′ UTR, reducing hnRNPD levels.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Low-Density Lipoprotein Receptor mRNA Degradation (LDLR mRNA Degradation).